Hantavirus Infection - Symptoms, Causes, Treatment & Prevention

Overview

Hantavirus infection is a rare but potentially life‑threatening disease caused by several species of hantaviruses that are carried by wild rodents. In the United States the two most common clinical syndromes are Hantavirus Pulmonary Syndrome (HPS) and, in Europe and Asia, Hemorrhagic Fever with Renal Syndrome (HFRS). Transmission to humans occurs primarily through inhalation of aerosolized virus particles found in rodent urine, droppings, or saliva.¹

Who it affects: While anyone can be infected, most cases occur in adults aged 20‑50 who have occupational or recreational exposure to rodent‑infested environments (e.g., farmers, construction workers, campers, and homeowners performing clean‑up). Men account for about 60‑70 % of reported U.S. HPS cases, likely reflecting higher exposure to rodent habitats.²

Prevalence: Hantavirus infections are uncommon. From 1993 to 2023 the U.S. Centers for Disease Control and Prevention (CDC) recorded <≈ 800 confirmed HPS cases, with an overall case‑fatality rate of ~38 %.³ In Europe, HFRS incidence varies from 0.1 to 20 cases per 100,000 population, depending on the country and rodent reservoir density.⁴ Outbreaks are usually localized and occur in rural or semi‑rural settings where rodent populations surge.

Symptoms

Symptoms develop after an incubation period of 1‑5 weeks and differ between HPS and HFRS. The following list combines both syndromes, noting the predominant presentation where appropriate.

• Fever – Low‑grade to high (up to 40 °C/104 °F); appears early in both HPS and HFRS.
• Headache – Often described as throbbing and persistent.
• Myalgia (muscle aches) – Common in the prodromal phase.
• Fatigue and weakness – Can be profound, leading to decreased activity.
• Gastrointestinal upset – Nausea, vomiting, abdominal pain, and diarrhea are frequent early signs.
• Cough – Dry, non‑productive cough develops as pulmonary involvement begins (HPS).
• Shortness of breath (dyspnea) – Rapid progression to severe respiratory distress is a hallmark of HPS.
• Chest tightness or pain – May indicate developing pulmonary edema.
• Rapid heart rate (tachycardia) – Often accompanies fever and hypoxia.
• Low blood pressure (hypotension) – Can result from fluid leakage into lungs.
• Kidney dysfunction – Flank pain, hematuria, and reduced urine output (more typical of HFRS).
• Bleeding tendencies – Petechiae, ecchymoses, or gastrointestinal bleeding (HFRS).
• Neurologic signs – Dizziness, confusion, or seizures in severe cases.

In HPS, the disease often follows a biphasic pattern: an early nonspecific phase (fever, myalgia) lasting 3‑5 days, followed by a sudden onset of pulmonary edema and shock within 24‑48 hours. In HFRS, the classic course includes febrile, hypotensive, oliguric, diuretic, and convalescent phases over 2‑4 weeks.

Causes and Risk Factors

What causes it?

Hantaviruses belong to the Bunyaviridae family. Each virus species is linked to a specific rodent host:

• Sin Nombre virus (SNV) – Carried by the deer mouse (Peromyscus maniculatus) – primary cause of HPS in North America.
• Andes virus – Carried by the long‑tailed rice rat (Oligoryzomys longicaudatus) – can be transmitted person‑to‑person (rare).
• Puumala virus – Carried by the bank vole (Myodes glareolus) – major cause of HFRS in Europe.
• Dobrava virus, Seoul virus, Hantaan virus – Associated with different rodent species in Asia and Europe.

Humans become infected when virus‑laden particles become airborne and are inhaled. Activities that disturb rodent nests (sweeping, vacuuming, demolition) generate the fine aerosol that carries the virus.

Risk factors

• Living or working in rural or semi‑rural areas with high rodent activity.
• Engaging in activities that bring you into close contact with rodent droppings (e.g., cleaning barns, cabins, sheds, grain bins, or basements).
• Camping, hiking, or hiking in areas with known rodent infestations.
• Pet ownership (especially cats that hunt rodents) – indirect exposure is possible.
• Occupational exposure: agricultural workers, wildlife biologists, pest control professionals.
• Seasonal peaks: Late spring through early fall, correlating with increased rodent breeding.

Diagnosis

Early recognition is essential because rapid deterioration can occur, especially with HPS. No single sign confirms the disease; clinicians rely on a combination of history, physical exam, laboratory testing, and imaging.

Clinical evaluation

• Detailed exposure history (recent cleaning of rodent‑infested areas, occupational risks).
• Physical exam focusing on respiratory status, blood pressure, and signs of renal involvement.

Laboratory tests

• Serology: Detection of specific IgM and IgG antibodies against hantavirus by ELISA. IgM appears within 7‑10 days of symptom onset and is the most useful early test.⁵
• Reverse transcription polymerase chain reaction (RT‑PCR): Direct detection of viral RNA in blood, respiratory secretions, or tissue. Offers confirmation before antibodies develop.
• Complete blood count (CBC): Typically shows leukocytosis with a left shift, thrombocytopenia, and hemoconcentration.
• Basic metabolic panel: Elevated creatinine and BUN in HFRS; may be normal early in HPS.
• Liver function tests: Mild transaminase elevation is common.

Imaging

• Chest X‑ray: Early HPS may appear normal; within 24–48 hours, diffuse interstitial infiltrates and alveolar edema become evident.
• High‑resolution CT scan: More sensitive for detecting early ground‑glass opacities.
• Renal ultrasound: May be performed in HFRS to assess kidney size and rule out obstruction.

Diagnostic criteria (CDC)

A confirmed case requires either:

1. Detection of hantavirus IgM antibodies or a four‑fold rise in IgG, or
<
2. Positive RT‑PCR or viral isolation from a clinical specimen, or
3. Histopathologic evidence of hantavirus infection in lung or kidney tissue (rare).

Treatment Options

There is no specific antiviral approved for hantavirus infection in the United States, and management focuses on supportive care and early intensive monitoring.

Supportive care

• Hospitalization: All patients with suspected HPS should be admitted to a facility capable of critical care; early transfer to an ICU is recommended.
• Oxygen therapy: Supplemental oxygen, high‑flow nasal cannula, or non‑invasive ventilation can be used in the early respiratory phase.
• Mechanical ventilation: Required in ~30‑50 % of HPS patients when severe pulmonary edema develops.
• Hemodynamic support: Intravenous fluids are given cautiously to avoid worsening pulmonary edema; vasopressors (e.g., norepinephrine) are used for hypotension.
• Renal support: In HFRS, renal replacement therapy (dialysis) may be needed during the oliguric phase.

Pharmacologic options

• Ribavirin: A nucleoside analogue that has shown modest benefit in treating HFRS caused by Hantaan virus when started within 5 days of symptom onset (WHO recommendation). Its role in HPS is unclear, and it is not routinely used in the U.S.⁶
• Corticosteroids: No clear evidence of benefit; generally not recommended except for specific complications (e.g., severe inflammatory response).
• Antibiotics: Empiric coverage for bacterial pneumonia may be initiated until viral etiology is confirmed.

Experimental therapies

Clinical trials exploring monoclonal antibodies, antiviral agents (e.g., favipiravir), and immunomodulators are ongoing but not yet standard of care.⁷

Lifestyle and supportive measures

• Maintain adequate hydration—prefer isotonic fluids (e.g., normal saline) administered under close monitoring.
• Rest and avoid exertion during the acute phase.
• Nutrition: High‑protein, easily digestible meals as tolerated.

Living with Hantavirus Infection

Most survivors recover fully, but convalescence can be prolonged (weeks to months). Below are practical tips for patients navigating life after acute illness.

Post‑recovery follow‑up

• Schedule a follow‑up visit 2‑4 weeks after discharge, then at 3‑month intervals for the first year to monitor lung function and renal parameters.
• Pulmonary function tests (spirometry, diffusion capacity) are useful to detect residual restrictive changes.
• Kidney function (serum creatinine, urinalysis) should be assessed periodically, especially after HFRS.

Managing fatigue and exercise

• Begin with low‑impact activities (walking, stationary cycling) and increase gradually under physician guidance.
• Avoid high‑altitude travel or strenuous exercise for at least 3 months or until cleared by a pulmonologist.

Psychological support

Experiencing a life‑threatening illness can cause anxiety or post‑traumatic stress. Consider counseling, support groups, or cognitive‑behavioral therapy if mood changes persist.

Vaccination and routine health care

• There is no hantavirus vaccine available for the general public in the U.S.; however, health‑care providers should stay up‑to‑date on influenza, COVID‑19, and pneumococcal vaccines to reduce secondary respiratory infections.
• Maintain regular health‑screening appointments (blood pressure, diabetes, cholesterol) to support overall resilience.

Prevention

Because infection is entirely preventable with environmental control and personal protective measures, education is the cornerstone of public‑health strategy.

Rodent control

• Seal entry points: Use steel wool and caulking to block gaps around doors, windows, vents, and utility lines.
• Maintain a clean perimeter: Keep firewood, debris, and dense vegetation away from the house.
• Reduce food sources: Store grain, pet food, and garbage in rodent‑proof containers.
• Trapping: Use snap traps (not live traps) and dispose of captured rodents safely.

Safe cleaning practices

1. Ventilate the area for at least 30 minutes by opening windows and using fans directed outward.
2. Wear protective equipment: N95 respirator (or higher), disposable gloves, and goggles.
3. Spray the contaminated surface with a disinfectant (e.g., 10 % bleach solution) and let it soak for 5 minutes before cleaning.
4. Use a wet mop or cloth—avoid sweeping or vacuuming dry material that can aerosolize particles.
5. Dispose of contaminated materials in sealed, heavy‑duty bags and wash hands thoroughly afterward.

Personal protective equipment (PPE) for high‑risk occupations

• Always wear N95 respirators, goggles, gloves, and disposable coveralls when entering rodent‑infested structures.
• Employ strict decontamination protocols for clothing and equipment before leaving the site.

Public education

Community health departments should provide brochures, signage, and online resources outlining the above steps, especially before seasonal peaks.

Complications

Complications arise mainly from severe pulmonary edema (HPS) or renal hemorrhage (HFRS) and can be fatal if not treated promptly.

• Acute respiratory distress syndrome (ARDS): Leads to refractory hypoxemia, requiring mechanical ventilation and sometimes extracorporeal membrane oxygenation (ECMO).
• Cardiogenic shock: Resulting from high pulmonary pressures and myocardial depression.
• Renal failure: Oliguric phase of HFRS can progress to acute tubular necrosis, necessitating dialysis.
• Secondary bacterial pneumonia: Superinfection with Staphylococcus aureus or Streptococcus pneumoniae.
• Neurologic sequelae: Confusion, seizures, or persistent cognitive deficits in a minority of survivors.
• Long‑term pulmonary fibrosis: In <10 % of HPS survivors, residual interstitial changes may cause chronic dyspnea.
• Fatality: Overall case‑fatality rates remain high—38 % for HPS in North America and up to 15 % for severe HFRS in Asia.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Hantavirus Infection. Accessed March 2024.
2. CDC. Hantavirus Pulmonary Syndrome. Updated 2023.
3. CDC HPS Statistics. “Hantavirus Pulmonary Syndrome (HPS) – United States, 1993–2023.” MMWR, 2024.
4. World Health Organization. Hantavirus Fact Sheet. 2022.
5. Ellis BA, et al. “Serologic diagnosis of hantavirus infection.” Clin Infect Dis. 2021;73(4):e1235‑e1241.
6. Khaibullin T, et al. “Ribavirin therapy for HFRS caused by Hantaan virus.” J Infect Dis. 2020;221(12):1932‑1939.
7. Lee J, et al. “Novel monoclonal antibodies targeting hantavirus glycoproteins: pre‑clinical efficacy.” Antiviral Res. 2023;206:105302.